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Abstract
The view that clot time-based assays do not provide a sufficient assessment of an individual’s hemostatic competence,
especially in the context of anticoagulant therapy, has provoked a search for new metrics, with significant focus directed at
techniques that define the propagation phase of thrombin generation. Here we use our deterministic mathematical model
of tissue-factor initiated thrombin generation in combination with reconstructions using purified protein components to
characterize how the interplay between anticoagulant mechanisms and variable composition of the coagulation proteome
result in differential regulation of the propagation phase of thrombin generation. Thrombin parameters were extracted from
computationally derived thrombin generation profiles generated using coagulation proteome factor data from warfarin-
treated individuals (N=54) and matching groups of control individuals (N=37). A computational clot time prolongation
value (cINR) was devised that correlated with their actual International Normalized Ratio (INR) values, with differences
between individual INR and cINR values shown to derive from the insensitivity of the INR to tissue factor pathway inhibitor
(TFPI). The analysis suggests that normal range variation in TFPI levels could be an important contributor to the failure of the
INR to adequately reflect the anticoagulated state in some individuals. Warfarin-induced changes in thrombin propagation
phase parameters were then compared to those induced by unfractionated heparin, fondaparinux, rivaroxaban, and a
reversible thrombin inhibitor. Anticoagulants were assessed at concentrations yielding equivalent cINR values, with each
anticoagulant evaluated using 32 unique coagulation proteome compositions. The analyses showed that no anticoagulant
recapitulated all features of warfarin propagation phase dynamics; differences in propagation phase effects suggest that
anticoagulants that selectively target fXa or thrombin may provoke fewer bleeding episodes. More generally, the study
shows that computational modeling of the response of core elements of the coagulation proteome to a physiologically
relevant tissue factor stimulus may improve the monitoring of a broad range of anticoagulants.
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Introduction
The management of anticoagulant therapy has relied on clot-
based assays such as the prothrombin time (PT) assay. In the case
of warfarin therapy, it has been established in clinical studies that a
prolonged clot time in the PT assay, after normalization to
account for reagent variability (expressed as the International
Normalized Ratio, INR) in the 2 to 3-fold range indicates a
sufficient level of anticoagulation in many patients [1]. However,
the efficacies of newer generation anticoagulants like dabigatran
etexilate [2] and rivaroxaban [3] are not well represented by the
PT assay. A generally applicable method to evaluate all classes of
anticoagulants is lacking.
A limitation of clot based assays is that more than 95% of
thrombin generation occurs after clot formation, whether studied
in plasma [4] or whole blood [5] or in reconstructions of the
coagulation proteome using purified proteins [6]. Post-clot
thrombin generation (i.e. propagation phase) is often characterized
in terms of parameters describing features of its dynamics, e.g.
maximum (max) rates and levels of formation. Numerous studies
have concluded that appropriate levels of propagation phase
thrombin formation appear critical to the coagulation process via
stabilization and maintenance of the barrier function of the blood
clot [7–9]. In addition, methods that present the entire course of
thrombin generation during a coagulation event demonstrate an
increased capacity, relative to clot based assays, to distinguish
between control individuals or between individuals characterized
by the same inherited disorder of the coagulation process [10].
One source of this increased discrimination derives from the
collective effects of normal range variation in coagulation factor or
inhibitor concentrations between individuals combined with the
use of a concentration of tissue factor (Tf) stimulus more consistent
with that characterizing intravascular lesions [11] (i.e. low pM Tf
versus 5 to 10 nM Tf in the PT assay).
Empirical evaluations of various anticoagulants using compre-
hensive thrombin generation assays have demonstrated dose-
related effects on clot times and on post-clot thrombin parameters
[12,13] and have shown differences between anticoagulants with
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sion. These studies however do not explicitly address the
mechanistic basis for these differences between anticoagulants or
differences in the response to a given anticoagulant among
individuals that have been observed [14].
In this study, computational and empirical approaches are taken
to relate propagation phase thrombin generation and anticoagu-
lant efficacy. Specifically, analyses of thrombin generation during
warfarin anticoagulation serve as a point of reference for empirical
and computational studies detailing the dynamics of the
suppression of thrombin generation for each of three anticoagu-
lants currently in use or in clinical trials (unfractionated heparin
(UFH), fondaparinux (Fpx), the direct fXa/prothrombinase (fXa-
fVa) inhibitor rivaroxaban), and a generic reversible thrombin
inhibitor.
Results
Model Representations of Warfarin Anticoagulated
Individuals
We have previously shown that contact pathway inhibited blood
samples from individuals with similar levels of warfarin anticoag-
ulation (INR 1.9–2.5) and no reported bleeding pathology exhibit
significant variability in their Tf-initiated coagulation response [15].
Plasma composition data determined at the time of that study for
each of the warfarin treated and control individuals are used here to
generate a model representation of the changes in Tf-initiated
thrombin generation associated with warfarin anticoagulation.
Table 1 (study 1) presents the mean factor composition values for
an anticoagulated group (N=7), one individual assessed 8 times
over 6 months and the control group (N=5) for this study. Table 1
(study2)presentsthemeanfactorcompositionlevelsfromaseparate
study for a larger warfarin treated group (N=47, shown as INR
ranges of 2 to 2.4 and 2.5 to 2.9) and a matching control group
(N=32). There are no corresponding whole blood data for this
second group. Levels of antithrombin, TFPI, fV and fVIII are
within the normal range for all individuals in the two warfarin study
groups, as are the VKD protein levels in the 2 control groups.
Figure 1A presents cTGPs for 7 individuals from study 1 with
INR values between 1.9 and 2.5. Figure 1B presents cTGPs for
one warfarin anticoagulated individual from study one sampled
over a 6 month period along with a cTGP representing that
individual after the cessation of therapy (INR=1). Direct
inspection of the cTGPs in both Figures 1A and 1B shows that
the relative intensity of thrombin generation is not explicitly
related to the INR, consistent with the results of the whole blood
study examining the response these individuals to a Tf stimulus of
the same magnitude [15]. For example the cTGPs of two
individuals each with INR values of 2.3 shown in Figure 1A are
characterized by thrombin parameters max rate and max level
that differ by 2 fold. Disparities of similar magnitude between the
cTGPs of warfarin-treated individuals with the same INR are also
observed in the larger warfarin groups. Figure 1C shows cTGPs
from three individuals with INR 2.3 with those from 5 individuals
with INRs of 2.7.
To develop general criteria to define a model representation of
successful warfarin anticoagulation, thrombin parameters were
extracted from the cTGPs of the individuals in each of the two
empirically studied warfarin-treated groups, as well as the control
group of that empirical study (5 control individuals or 32
individuals). The values of the thrombin parameters of the
warfarin-treated groups were then expressed relative to the
corresponding parameter values of the matching control group
values (Table 2). The comparison of model predicted clot times
between control and anticoagulated individuals yielded a ratio
value analogous to the ratio (INR) between a patient’s prothrom-
bin time and that of a standard plasma sample. For the group of
seven warfarin treated individuals in study 1, the average cINR
(2.360.4) was consistent with the clinically determined INR values
(2.260.2) and overlapped with the prolongation of clotting
reported in the whole blood study of these individuals (2.160.6)
[15]. Good correspondence was also observed when cINR and
INR values for the one individual studied multiple times.
Additional features of the cTGPs of these warfarin-treated
individuals include a ,70 to 80% suppression in the both the
max rate and level of thrombin produced as well as total thrombin
generated. Similarly, when the larger warfarin-treated group
(N=47, subdivided into two groups based on INR) was subjected
to the same type of analysis and their cTGPs expressed as a ratio
relative to their control group (N=32), cINR values showed good
correspondence with their respective plasma based INR values
(Table 2).
Table 1. Coagulation factor levels*.
N FII FVII FIX FX AT FV FVIII TFPI
Study 1
Control 5 98.0 (16.0) 83.4 (14.4) 107.8 (25.8) 86.4 (13.9) 94.6 (10.9) 101.6 (26.7) 149.4 (37.4) 91.7
(4.4)
Warfarin (Group) 7 24.7 (5.3) 41.6 (11.8) 45.0 (12.7) 15.9 (4.7) 98.4 (8.9) 97.4 (27.0) 198.3 (47.3) 75.3
(6.0)
Warfarin (Individual) { 8 24.9 (3.8) 34.8 (8.6) 37.9 (5.5) 15.0 (3.4) 107.0 (9.5) 138.9 (10.3) 126.6 (11.2) 86.0
(11.6)
Study 2
Control 32 110.7 (14.8) 107.7 (17.1) 120.2 (19.9) 119.1 (20.6) 100.0 (13.5) 108.7 (12.3) 139.5 (26.7) 114.3 (16.8)
Warfarin
(INR 2.0–2.4)
25 35.4 (9.9) 30.5 (8.9) 32.3 (6.8) 37.2 (11.3) 108.0 (15.9) 104.3 (15.0) 132.3 (33.1) 104.2 (27.8)
Warfarin
(INR 2.5–2.9)
22 26.2 (5.1) 31.9 (9.7) 34.4 (7.6) 37.7 (9.0) 103.7 (9.7) 106.8 (14.0) 117.2 (30.4) 110.3 (37.2)
*Mean (SD) expressed as a percentage of each factors mean physiologic level.
{One individual studied at eight separate times over a six month period.
doi:10.1371/journal.pone.0027852.t001
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27852Figure 1. Model representation of individuals stablely anticoagulated with warfarin. Computationally derived thrombin generation
profiles reflecting each individual’s actual ensemble of factor levels are presented with each anticoagulated individual’s profile identified by his
clinically determined INR value. A thrombin generation profile characterizing a hypothetical individual with all factors at mean physiologic levels is
also shown. Panel A, 7 individuals; Panel B, One warfarin treated individual assessed 8 times over 6 months and after warfarin therapy was ended
(INR=1); Panel C, 7 individuals from study 2 with INR values of 2.3 or 2.7. Note the difference in Y-axis scale.
doi:10.1371/journal.pone.0027852.g001
Table 2. Computational analysis on individuals on warfarin.
N Fold Prolongation % Max Rate % Max Level % AUC Plasma INR
Study 1*
Warfarin Group 7 2.3 (0.4) 29 (14) 24 (9) 20 (7) 2.2 (0.2)
Warfarin Individual{ 8 2.5 (0.4) 17 (6) 17 (6) 18 (5) 2.3 (0.2)
Study 2{
INR 2.0–2.4 25 2.38 (0.60) 18.2 (8.5) 20.4 (7.1) 25.2 (9.6) 2.2 (0.14)
INR 2.5–2.9 22 2.66 (0.70) 14.2 (8.5) 15.7 (6.2) 19.3 (7.0) 2.7 (0.14)
*Plasma composition data from individuals on warfarin and a control group (n=5) were used to construct computational thrombin generation profiles from which
thrombin parameters clot time, maximum rate of thrombin generation (Max Rate), maximum level of thrombin generation (Max Level) and total thrombin (AUC) were
extracted. The parameter data are presented as mean (SD) for either a ratio or a percentage between warfarin treated and control individuals.
{One individual studied at eight separate times over a six month period.
{47 anticoagulated patients were divided into two groups based on their INR and their thrombin generation modeled. Thrombin parameters were extracteda n d
compared to the control group (n=32) as in study 1.
doi:10.1371/journal.pone.0027852.t002
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data comparing thrombin generation by an ‘‘average’’ warfarin-
treated individual, constructed using the mean factor levels for the
seven warfarin-treated individuals modeled here in study 1, with
an ‘‘average’’ control individual, reflecting the mean physiologic
values of the study 1 control group [16]. Consistent with the
current computational analysis, the prior empirical reconstruction
of the ‘‘average’’ warfarin treated individual displayed a 2.4 fold
prolongation of the initiation phase (clot time) with a ,85%
suppression of the max rate and level of thrombin generation
relative to the ‘‘average’’ control.
Analyses of cINR and INR differences on an individual
basis
When the correspondence between plasma derived INR values
and cINR values was examined for each individual in study 2
(N=47), we observed that in 19 (40%) cases the difference was less
than 10%, but that more significant differences occurred in the
majority of comparisons. We investigated the potential for these
differences to derive from variation in specific factor levels by
establishing a metric which quantified the relative disparity
between model and PT assay derived values for each individual.
Figure 2 presents the results of linking this metric for each
individual to that individual’s level of TFPI, as percent of the mean
physiologic value, and then assessing the overall trend between the
magnitude of the difference between the cINR and INR and TFPI
level for the entire population. The result is a strong correlation
between the magnitude and direction of the discrepancy and the
TFPI level, as reflected in the r
2 value (0.511, p,0.001). Similar
analyses were formed with all other factors and yielded the
following r
2 values: fVII (0.217, p=0.001), fVIII (0.199,
p=0.002), AT (0.122, p=0.016), and for fII, fV, fIX and fX the
r
2 values were below 0.05 (all p.0.3). In contrast, for the same
population, when plasma derived INR values for each individual
were plotted directly against the levels of each of their factors, the
correlation with fII was strongest (r
2=0.37, p,0.001) followed by
FVIII (r
2=0.068, p=0.08), with all others r
2 below 0.02,
including fVII (all p.0.3). Thus the computational analysis,
which, unlike the PT assay, reflects the inhibitory effects of TFPI
on thrombin generation, suggests that the effectiveness of the INR
as a measure of an individual’s level of anticoagulation may be
lessened in individuals characterized by TFPI levels approaching
the extreme of its normal range (46–171% of mean physiologic).
In the study 2 population, 11 of the 47 warfarin-treated
individuals had cINR values below 2, suggesting they were
potentially under anticoagulated. Three of these individuals
suffered thrombotic events subsequent to their reported INR
determination (individuals are indicated in Figure 2). INR values
for these three were 2.1, 2.2 and 2.5 while their cINR values were
1.7, 1.8 and 1.5 respectively; respective TFPI concentrations were
77%, 73% and 72%.
Empirical validation of modeling of coagulation
proteome variation
Previously we have shown in both empirical [17] and
computational approaches [18] that normal individuals exhibit
significant phenotypic individuality in their Tf-dependent coagu-
lation responses. In this study, when the 37 control individuals are
considered collectively, modeling derived thrombin parameters
such as max rate, max level and total thrombin vary over a 2 to 3
fold range in this group while predicted clot times range between
,170 and 250 s, all well within the range reported when cTGPs
from 473 control individuals from the Leiden Thrombophilia
Study were analyzed [18].
Figure 3A shows cTGPs for 2 control individuals (study 1),
where every factor level of these individuals is within the normal
Figure 2. Dependence of differences between INR and cINR values on TFPI levels. The difference between each individuals (N=47) INR
and cINR was expressed as a percent of the INR [(cINR-INR)/INR] and then plotted against each individual’s TFPI level expressed as a percent of mean
physiologic. Individuals with high normal TFPI levels display positive ratio values while those with low normal values display negative ratios. Linear
regression analysis yielded the following expression y=101.65x + 105.4 with an r
2=0.51. The predicted y intercept, representing the TFPI
concentration where cINR and INR values do not diverge, correlates well with the mean TFPI value for the population (see Table 1). The three
individuals that had a thrombotic event subsequent to the blood draw for compositional analysis are indicated in red.
doi:10.1371/journal.pone.0027852.g002
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AUC differ ,2 fold while the clot time parameter increased
from 173 s (A) to 250 s (E). The differences between the two
profiles derive from differences in plasma factor composition: in
this case, all procoagulant factors (fII, fV, fVII, fVIII, fIX, fX)
are at higher levels (33–62%) in individual A while TFPI and
AT levels are similar between A and E. Also shown (Figure 3A)
are two TGPs for synthetic proteome mixtures constructed to
reflect the specific factor levels of two of these individuals. The
empirical reconstruction is consistent with the predicted
variation between the two individuals, with the thrombin
parameters max rate, max level, clot time parameter and
AUC showing the same percentage difference. A good direct fit
between empirical and model data is evident for the max rate
and clot time parameters but the max level is ,23% lower in
both empirical reconstructions and a difference in AUC is
observed. Overall, the correspondence is reasonable and
demonstrates the ability of this combined approach of modeling
and empirical proteome reconstructions with purified proteins
to capture the dynamic consequences of normal range variation
in coagulation factor ensembles.
It should be noted that the concept of reasonable correspondence
acknowledges the reality of the tension between the variability
inherent inthe empirical reconstructions and the invariantnature of
model parameters. Specifically, synthetic proteome reactions
involve 10 purified proteins, natural and recombinant, each
reflecting the variability characteristic of any single protein
preparation. In contrast, the deterministic mathematical model
uses empirically measured rate constants, often averaged from
multiple independent studies, and operates as if they, and initial
species levels, are known without error [19]. Because of this, model
parameters in this study are not adjusted to better fit empirical data
from synthetic coagulation proteome experiments.
Empirical validation of modeling of coagulation
proteome variation: responses to anticoagulants
The effects of individual variation in coagulation factor
composition on the response to anticoagulants were then assessed.
Figure 3 (B-D) shows TGPs from synthetic proteome mixtures,
along with corresponding cTGPs, constructed to reflect the
specific factor levels of the same two individuals (A and E, see
Figure 3A for controls) with either 4 nM, 10 nM or 21 nM
Figure 3. Empirical and computational studies of coagulation factor-based variability in thrombin generation in 2 control
individuals in the presence or absence of rivaroxaban. cTGPs for 2 individuals (A,E) (open symbols) based on their plasma factor composition
with corresponding empirical thrombin generation (closed symbols) measured in synthetic coagulation proteome reconstructions. Panel A, no
rivaroxaban; Panel B, 4 nM rivaroxaban; Panel C, 10 nM rivaroxaban; Panel D, 21 nM rivaroxaban. Predicted thrombin concentrations are given at time
points to match empirical sampling, which is performed at 1 minute intervals.
doi:10.1371/journal.pone.0027852.g003
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the level of fidelity between cTGPs and empirical reconstructions
when the kinetic parameters for anticoagulant action are well
known. For example, analysis of the cTGPs for individuals A and E
indicates that 10 nM rivaroxaban (figure 3C vs figure 3A) prolongs
the clot time 2.6 fold, suppresses the maximum level ,35% and the
max rate ,60%.In the empirical reconstructions the presenceof 10
nM rivaroxaban results in an average 2.3 fold prolongation of clot
time, a 45% suppression of the max level and a 50% suppression of
the max rate. Similar comparisons of cTGPs and empirical
reconstructions were successfully performed for each anticoagulant
in this study across several concentrations to validate the model
descriptions (data not shown). We have previously reported cTGPs
and TGPs both constructed with all factors at mean physiologic
levels comparing rivaroxaban and Fpx [16].
Model representations of the alterations in the
propagation phase of thrombin generation in individuals
subjected to different anticoagulants
The relationship between the variability in the coagulation
proteomes of individuals, the mechanisms characterizing differ-
ent anticoagulants and the relative effectiveness of these
anticoagulants in different settings remains unclear. In light of
this, modeling based analyses were carried out to systematically
compare propagation phase alterations by 5 anticoagulants
tested at different concentrations in the same group of
individuals (N=32). Previous reports [16,20–22] and the current
study have demonstrated reasonable correspondence between
modeled thrombin generation and empirical reconstructions in
studies focusing on population differences and anticoagulant
efficacy, suggesting that the modeling approach would have
some relevance in comparing anticoagulant responses. To carry
out this study using the synthetic coagulation proteome would
require a minimum of 350 separate experiments and would be
unfeasible.
The consequences of the interaction between variability
between individuals in thrombin generation potential (based on
plasma coagulation factor composition) and differences in
anticoagulant mechanism on propagation phase dynamics are
presented for warfarin (Figure 4), two AT dependent agents (UFH,
Fpx), rivaroxaban and a reversible thrombin inhibitor (DAPA)
(Figure 5).
Figure 4. Model representation of hypothetical warfarin anticoagulation of control individuals. cTGPs are presented for individuals
before (e.g. A) and after hypothetical warfarin therapy (e.g. A’) achieved by setting all VKD proteins at 33% their mean physiologic values with other
factors retaining their individual specific values. Panel A: cTGPs of 5 control individuals with an additional cTGP representing an individual with all
factors at 100% mean physiologic level. Panel B: 2 individuals with the most disparate thrombin generation profiles prior to anticoagulation. Panel C:
2 individuals with the most similar thrombin generation profiles prior to anticoagulation.
doi:10.1371/journal.pone.0027852.g004
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The average of all four VKD protein levels (Table 1, study 2) in
each warfarin-treated group analyzed in Table 1 is ,30% of its
mean physiologic value. Guided by this average distribution,
hypothetical warfarin anticoagulation was modeled in the 32
control individuals by setting the VKD protein levels to 25% or
33% that of their mean physiologic value while the concentrations
of the other factors were left at their individual specific levels
(Table 3). cTGPs for each of the 32 individuals in the larger
control group after hypothetical anticoagulation were calculated
and expressed relative to the pretreatment thrombin parameter
values of that individual to give a percent change in each thrombin
parameter. Group averages of these percent change values for
each parameter were then generated (Table 3). Thus in these
comparisons, unlike those presented in Figure 1, each individual
has the same specific level of suppression of VKD proteins. At
33%, the model predicted group average prolongation of clot time
was about 2.2 fold (cINR=2.2) and there was ,75–80%
suppression of all three thrombin parameters. At a 25% VKD
protein level, prolongation of clot time for the group was about 2.8
fold (cINR=2.8) with ,80–85% suppression of thrombin
parameters. The average change in model-derived thrombin
parameters reported for the warfarin-treated individuals with
average INRs of 2.2 or 2.7 (Table 2: study group 2) were in good
accord with the results of hypothetical VKD suppression at 33%
and 25% respectively.
This correspondence between computational representations of
actual and hypothetical individuals on warfarin therapy provides a
rationale and justification for using the same healthy population to
computationally model the efficacy of other anticoagulants and
thus compare the responses of the same individuals to different
anticoagulant therapies on the basis of their individual coagulation
factor ensembles.
Figure 4A presents the cTGPs for five control individuals (study
1) with relatively distinct cTGPs while Figure 4B and 4C show the
response of four of the control individuals to hypothetical warfarin
anticoagulation. With the two disparate individuals (A and E),
equivalent levels of VKD suppression yield cTGPs that differ by
less than 10% in the three thrombin parameters. In contrast, in the
individuals (C and D) with relatively equivalent cTGPs, an
equivalent level of VKD suppression results in a ,30% difference
in all thrombin parameters. Additionally individuals D and E,
despite ,50% differences in all thrombin parameters prior to
hypothetical VKD suppression, respond to equivalent levels of
Figure 5. Computational thrombin generation profiles reporting the response of 5 control individuals to anticoagulation.
Anticoagulant concentrations are used that yield a group averaged cINR of ,2.1 for each anticoagulant. Panel A, 1.25 nM UFH. Panel B, 100 nM Fpx.
Panel C, 6 nM rivaroxaban. Panel D, 0.5 mM DAPA. Note for these 5 individuals the average sensitivity to Fpx and DAPA was different than the 32
individuals in Table 3.
doi:10.1371/journal.pone.0027852.g005
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patterns remain when the same comparisons between individuals
at the 25% VKD level are made (not shown). Overall the range of
variability in cTGPs among the individuals prior to ‘‘treatment’’ is
preserved after hypothetical warfarin anticoagulation but does not
directly reflect the relative ranking of thrombin generation
intensity prior to ‘‘therapy’’. The computational analysis makes
it clear that normal range variations in plasma factor composition
result in unique ensembles of non-VKD dependent proteins that is
an important contributor to the anticoagulation phenotype
achieved with warfarin and not just the variable levels of VKD
proteins that result from actual warfarin therapy (see Table 1).
Thus hypothetical warfarin anticoagulation appears to reproduce
both the cINR and the specific alterations in thrombin parameters
characterizing actual warfarin-treated populations as well as the
unpredictability (variability) of the outcome [15].
Anticoagulation by mechanistically distinct inhibitors
Computational TGPs reporting the ‘‘responses’’ of the same 32
control individuals to anticoagulation by UFH, Fpx, rivaroxaban,
and DAPA were generated for a number of concentrations of
each anticoagulant. The concentrations of each anticoagulant
which gave a group averaged cINR of ,2.1 and of ,2.7 were
selected for comparison to the cTGPs for the same individuals
undergoing hypothetical warfarin therapy. This allowed the
comparison of propagation phase parameters at the same clot
time prolongation value (i.e. the same INR). These data are
summarized in Table 3.
UFH
Active heparin molecules, constituting 30 to 40% of UFH
preparations, bind to and conformationally activate the stoichio-
metric inhibitor AT, increasing its reactivity with thrombin (10
3
fold) [23], fXa (10
4 fold) [24,25], fIXa (10
6 fold) [26] and Tf-fVIIa
(20 fold) [27]. A large percentage of UFH molecules appear to
bind to plasma proteins and various blood cells [28] (Table 4).
Figure 5A presents representative cTGPs in the presence of 1.25
nM UFH (0.01 units/mL) for 5 selected individuals A to E, with
the group (N=32) averaged changes in thrombin parameters
presented in Table 3. The group averaged cINR for these cTGPs
was 2.160.1, comparable to that achieved with these individuals
at a hypothetical warfarin induced VKD level of 33%
(cINR=2.260.1). When propagation phase features of UFH
anticoagulation were evaluated, this concentration of UFH yielded
reductions in the thrombin parameter max rate similar to those
observed with the hypothetical warfarin group and to those
observed with the actual warfarin group (study group 2, INR 2–
2.4, Table 2). However the suppression of the parameters max
level and total thrombin by UFH was not as robust as in both
hypothetical and actual warfarin groups. At a concentration of
UFH that yielded a cINR of 2.7, approximately equivalent to that
observed with hypothetical warfarin induced VKD level of 25%,
the same pattern was observed, with UFH anticoagulation
showing distinct differences from warfarin anticoagulation in the
same two propagation phase parameters. In addition, unlike
hypothetical warfarin therapy, the response to UFH is relatively
uniform between individuals, with the pretreatment order of
relative intensity of thrombin generation among the 5 individuals
(see Figure 4A) preserved with UFH anticoagulation. For example
suppression of the parameter max level in individual A is 35%,
while in individual E it is 34%. This contrasts with the response to
hypothetical warfarin coagulation (Figure 3A) where max level is
suppressed ,85% in individual A and ,33% in individual E.
Table 3. Comparison of anticoagulants at a constant cINR*.
% Pre-anticoagulation
Anticoagulant
Fold Prolongation
(cINR) Max Rate Max Level AUC
Warfarin 33% VKD{ 2.20 (0.13) 19 (3.0) 21 (2.8) 25 (5)
Warfarin 25% VKD{ 2.80 (0.15) 12 (1.8) 14 (2.0) 19 (4)
1.25 nM UFH 2.14 (0.11) 19 (1.4) 34 (1.5) 55 (7)
1.75 nM UFH 2.66 (0.14) 13 (1.4) 27 (2.0) 40 (11)
6 nM Riva 2.08 (0.07) 92 (1.3) 71 (1.7) 99 (2)
10 nM Riva 2.60 (0.09) 41 (1.4) 63 (2.0) 90 (8)
0.3 mM DAPA 2.05 (0.05) 114 (3.6) 88 (1.3) 89 (3)
0.6 mM DAPA 2.76 (0.08) 101 (10) 73 (3.0) 72 (5)
125 nM FPX 2.14 (0.05) 87 (2.0) 90 (1.5) 96 (2)
250 nM FPX 2.69 (0.08) 79 (2.8) 84 (2.2) 72 (5)
*A computational analysis of the response of 32 control individuals to the
indicated anticoagulants. Thrombin parameters (see Table 2) were extracted
and expressed as the ratio of the post- to pre-treatment values. The cINR is the
ratio of the thrombin parameter ‘‘time to 10 nM’’ for each anticoagulation
concentration. Data are mean (SD), n=32.
{VKD: Vitamin K dependent proteins in each individual are set to 33 or 25
percent of the mean physiologic levels (other proteins remain at their
individual specific levels).
doi:10.1371/journal.pone.0027852.t003
Table 4. Properties of Anticoagulants.
Chemical Expression
Clinical Dose Range
(Prophylaxis)
UFH AT+UFHOAT-UFH 0.1 – 0.4 U/mL
a
Xa+AT-UFHRXa-AT+UFH
IXa+AT-UFHRIXa-AT+UFH
mIIa+AT-UFHRmIIa-AT+UFH
TF-VIIa+AT-UFHRTF-VIIa-AT+UFH
Va-Xa+AT-UFHRVa-Xa-AT+UFH
IIa+AT-UFHRIIa-AT+UFH
Fpx AT+FOAT-F 0.12 – 0.4 mM
b
Xa+AT-FRXa-AT+F
IXa+AT-FRIXa-AT+F
mIIa+AT-FRmIIa-AT+F
TF-VIIa+AT-FRTF-VIIa-AT+F
Va-Xa+AT-FRVa-Xa-AT+F
IIa+AT-FRIIa-AT+F
Rivaroxaban Xa+ROXa-R 0.02 – 0.31 mM
c
Va-Xa+ROVa-Xa-R
DAPA IIa+DAPAOIIa-DAPA 0.6 – 1.8 mM
d
mIIa+DAPAOmIIa-DAPA 0.08 – 0.39 mM
e
mIIa-DAPA+Xa-VaRIIa-DAPA+Xa-Va
a1U ; 170 nM functional heparin molecules; in blood, .90% of UFH may be
unavailable for binding with AT [28,45].
bFpx binds almost exclusively to AT in blood [34,46].
cCtrough –C max (10 mg once daily): 5 – 8% free in plasma [47,48].
dDose ranges for Argatroban, a structurally related reversible thrombin inhibitor
in clinical use (KD=20 nM) [49].
eCtrough –C max for Dabigatran (220 mg once daily), a reversible thrombin
inhibitor (KD=50 pM) [50,51].
doi:10.1371/journal.pone.0027852.t004
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Fpx is a synthetic pentasaccharide that reversibly binds with
high affinity (KD=36 nM [29]) to AT and increases its rate of
inhibition of fXa [23] and fIXa [26] ,100 fold (Table 4).
Figure 5B presents cTGPs for same individuals A to E in the
presence of 125 nM Fpx: the group averaged cINR is 2.160.1
(N=32), similar to that characterizing a hypothetical warfarin
induced VKD level of 33%, UFH at 1.25 nM and the actual
warfarin treated group (Table 2, study group 2:INR 2.0–2.4). As
can be seen by both visual inspection (compare to Figures 4, 5A)
and in thrombin parameter data (Tables 2, 3), Fpx anticoagulation
at equivalent cINR displays little suppression of thrombin
parameters max rate and level and almost no suppression of total
thrombin. The same relative lack of suppression of propagation
phase parameters is observed when the group averaged thrombin
parameters at a cINR of 2.7 are analyzed. Similar to UFH
anticoagulation, the response to Fpx is relatively uniform between
individuals. Thus features of Fpx anticoagulation differ substan-
tially from those of UFH and warfarin when compared at
equivalent cINRs.
Rivaroxaban
Rivaroxaban is a small molecule, reversible inhibitor that
selectively binds to the active site of fXa and fXa in the
prothrombinase complex [30]. Figure 5C presents cTGPs in the
presence of 6 nM rivaroxaban for individuals A to E: the group
averaged cINR is 2.160.1 (N=32). The overall quality of this
anticoagulation is quite similar to that achieved by 125 nM Fpx,
with the two anticoagulants showing almost equivalent suppression
of the thrombin parameters max level and max rate and a similar
lack of effect on total thrombin generated. Some differences
emerge between rivaroxaban and Fpx anticoagulation when their
thrombin parameters accompanying a cINR of 2.7 are compared
with rivaroxaban, having more pronounced suppression of the
parameters max rate and level. Like UFH and Fpx anticoagula-
tion, the response to rivaroxaban is uniform between individuals,
consistent with the results of the empirical reconstructions
comparing anticoagulation by rivaroxaban of individuals A and
E (Figure 3, B-C).
DAPA
DAPA is a reversible, active site directed inhibitor of thrombin
and meizothrombin (mIIa), with a KD of 20–40 nM [31,32]. The
mIIa=DAPA intermediate [31] is processed to IIa=DAPA by
prothrombinase. Similar to Argatroban [32], a structurally
related thrombin inhibitor in clinical use, the koff for the DAPA
thrombin complex is in the range of 0.04 to 0.07 s
21 (in house)
(Table 4).
Figure 5D presents cTGPs in the presence of 0.3 mM DAPA.
Examination of DAPA anticoagulation of individuals A to E
shows it lacks the effectiveness of either warfarin or UFH in
suppressing propagation phase parameters when compared at
either a group averaged cINR of 2.1 or 2.7 (Table 3). Relating its
efficacy to those of rivaroxaban and Fpx is less straightforward.
At a cINR of either 2.1 or 2.7, DAPA anticoagulation appears
similar to Fpx with respect to its effects on thrombin parameters
max level and total thrombin but differs in its striking
ineffectiveness in suppressing the parameter max rate. The level
of thrombin parameter suppression by DAPA is relatively
uniform among the five individuals. In general the features of
DAPA anticoagulation distinguish it from the other anticoagu-
lants in this study.
Summary of anticoagulant effects on the propagation
phase
The average thrombin generation phenotype associated with
warfarin anticoagulation reflects a more robust suppression of all 4
thrombin parameters than any of the other anticoagulants. The
relative order of suppression displayed at the same cINR was:
warfarin . UFH . DAPA $ Fpx, rivaroxaban.
Discussion
In this study, we first compare model representations (i.e.
cTGPs) based on plasma coagulation factor composition data from
actual individuals successfully treated with warfarin to cTGPs
characterizing matching control populations. A metric—the
computational INR (cINR)—is defined and shown to correlate
well with the actual INR values of these individuals, thus providing
validation of the computational approach using the one clinical
measure available for the warfarin-treated individuals. When
analyzed on an individual by individual basis differences between
clinical INR and cINR values derive primarily from variations in
TFPI levels, to which the PT assay is insensitive.
The dependence of the discrepancy between the cINR and
plasma INR on the magnitude of the difference between an
individual’s TFPI level and the mean physiologic TFPI level
suggests a testable hypothesis: individuals with large differences
between INR and cINR are not at the expected level of
anticoagulation and should be more prone to adverse events.
Negative deviations in the (cINR-INR)/INR metric, associated
with low TFPI levels, suggest under-anticoagulation and thus a risk
of thrombotic events while large positive deviations would indicate
a relatively increased bleeding risk. Consistent with this implica-
tion of the computational analysis, the 3 individuals that had
thrombotic complications did display cINRs ,2, strong negative
deviations in the (cINR-INR)/INR metric and low TFPI levels.
However thrombotic complications were not reported for 5 other
individuals with similar parameters. A larger study would be
required to test the predictive capacity of this approach.
A central finding of these analyses is that none of these other
anticoagulants recapitulate all features of warfarin anticoagulation
when defined in terms of the pattern of propagation phase
thrombin formation. This conclusion is driven by the mechanistic
descriptions of each inhibitors interactions and is not limited to the
specific binding parameters and concentration ranges used in the
analyses of the examined inhibitors. Thus modeling results apply
generally to the entire classes of reversible thrombin inhibitors,
reversible fXa inhibitors, and low molecular heparins with
mechanisms of action similar to Fpx. For example, the direct
thrombin inhibitor dabigatran (Table 4) reproduces the pattern of
propagation phase parameter suppression observed with DAPA
when analysed at a cINR of 2.1 (data not shown).
The current analyses show that propagation phase parameters
(Table 3) are less affected by Fpx, rivaroxaban and DAPA than
warfarin and UFH when compared at concentrations that yield
equivalent cINR. Empirical reconstructions presented in this study
and previously [16] confirm the model predictions of relatively
robust propagation phase parameters for rivaroxaban and Fpx
relative to warfarin. Empirical reconstructions (not shown) of
DAPA and UFH anticoagulation are also consistent with model
representations. Similar results, i.e. relatively robust propagation
phase thrombin parameters at anticoagulant doses that prolong
the lag phase 2 to 3 fold, have been reported for dabigatran [12],
Fpx [13] and rivaroxaban [33] when assessed by plasma-based
thrombin generation assays.
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efficacies in computational, synthetic coagulation proteome and
whole blood models, we observed that Fpx efficacy was relatively
consistent between the 3 models and was in line with the
therapeutic usage range of Fpx. However, with rivaroxaban 10 to
20 times higher concentrations were required in whole blood
studies than predicted by computational and matching proteome
reconstructions, with these higher levels being in line with plasma
levels achieved during standard clinical use of rivaroxaban. We
hypothesized that these differences reflected the different func-
tional distributions of rivaroxaban and Fpx in the blood: Fpx is
almost exclusively bound to AT in human plasma [34] and
therefore fully available to participate in anticoagulation even in
whole blood while ,90 to 95% of rivaroxaban is bound to plasma
proteins [2], with the unbound fraction representing the
pharmacologically available fraction. Similarly, but in contrast to
Fpx, UFH exhibits strong binding to plasma proteins other than
AT as well as cellular elements [28]. Studies in our laboratory
(data not shown) testing UFH efficacy in whole blood show that to
achieve a ,2 fold prolongation in clot time, a UFH concentration
(0.05 to 0.1 U/ml) 5 to 10 times higher than in proteome and
computational models is required. Collectively, these data suggest
that the computational assessments of inhibitor efficacy may
represent the actual levels of anticoagulant in blood that are
dynamically available to suppress coagulation in vivo.
The significance of anticoagulant effects on clot time and
propagation phase thrombin generation needs to be viewed in the
context of 2 different environments: one is intravascular with
blood flowing over an emerging procoagulant lesion in a diseased
region of a blood vessel; and the other is the extravascular space to
which blood is transferred following perforating trauma to a blood
vessel [16]. In the first setting anticoagulation seeks to supplement
the natural antithrombotic properties of a vessel—the mechanical
and dilutional effects of flow and the antithrombogenic effects
(thrombomodulin, TFPI) contributed by neighboring endothelial
cells—by further reducing the inherent coagulability of the blood.
The desired result is to arrest the Tf-initiated process in the
initiation phase so that thrombus formation is prevented. Thus in
vitro tests focusing on clot time prolongation appear to be a
reasonable approach on theoretical grounds for calibrating
anticoagulant doses for this setting. Conversely tests that focus
on differences in propagation phase dynamics between inhibitors
may not be relevant in this context.
The second environment, the extravascular, is one both
relatively rich in Tf and the proteins that support platelet adhesion
while somewhat physically isolated from the antithrombotic forces
of the vascular environment. Here it is desirable in the context of
long-term anticoagulation that the anticoagulated blood supports
formation of an adequate clot in response to unexpected
perforating trauma to the blood vessel in an anticoagulated
individual. Thus here the criterion of clot time prolongation does
not appear relevant to comparing the relative suitability of
anticoagulants. However, to the extent that the quality of post-
clot thrombin generation is important to fibrin structure, barrier
maintenance and the wound healing processes [7,8], anticoagulant
effects on the propagation phase of thrombin generation may
represent an important discriminator for understanding the
relative levels of unwanted bleeding episodes associated with
different anticoagulants. The data from this study suggests that
thrombin and factor Xa directed inhibitors may have mechanistic-
based advantages over the more broadly based inhibitory effects of
warfarin and UFH therapies in this context since at doses that give
equivalent prolongation of clot times (cINR values), propagation
phase thrombin generation, once it begins, is more robust.
Successful long-term anticoagulant therapy occurs when a
balance is achieved between suppression of catastrophic procoag-
ulant responses at specific compromised site(s) within the
vasculature and maintenance of a reasonable level of repair
response to perforating trauma to the circulatory system. For any
anticoagulant, the ability to balance these two opposing goals at a
single dose theoretically derives in part from the differences
between the two settings in the size of the procoagulant stimulus.
For example, Tf expression contained within atherosclerotic
plaques has been reported as ,6 molecules/mm
2 [11] while a Tf
surface density of ,60 molecules/mm
2 has been reported for
human fibroblasts [35]. In the empirical studies presented here—5
pM surface available Tf and 2 mM PCPS vesicles—there are 3 to 4
Tf molecules/mm
2 of solution exposed phospholipid, comparable
to the estimates for the atheroma but not the extravascular milieu.
In order to provide a quantitative estimate of the impact of
differential expression of Tf on propagation phase parameters for
different anticoagulants, a preliminary computational analysis
(Table 5) was undertaken to establish what Tf concentration was
necessary to normalize the clot time in the presence of each
anticoagulant when the anticoagulant was present at a concentration
designed to give a cINR of ,2.1 at 5 pM Tf. The propagation phase
parameters of thrombin generation could then be compared to those
characterizing the 5 pM Tf stimulus in the absence of anticoagulants
to see which anticoagulants achieved ‘‘normal’’ thrombin generation
in the extravascular compartment. In general increased Tf
concentrations of only 2 to 4 fold were needed to achieve the
standard clot time in the absence of anticoagulants, independent of
the mechanism of the anticoagulant. With rivaroxaban, Fpx and
DAPA this resulted in propagation phase parameters as robust as or
moresothan that of the control.However, in the case of warfarin and
UFH anticoagulation all propagation phase parameters remained
suppressed by ,2f o l do rm o r e .
In summary, our results indicate that computational methods
focusing on thrombin generation can discriminate between
different anticoagulants compared at equivalent cINR and
between different individuals on the same anticoagulation
regimen, supporting the idea that this approach can contribute
to the management of anticoagulant therapy. The question with
the use of anticoagulants, or more generally at all therapies
directed at redressing blood clotting disorders, is how much you
need to know about each individual’s coagulation system to
improve outcomes. Empirical thrombin generation assays require
only citrate plasma samples and samples of potential anticoagu-
lants to provide an immediate readout of thrombin generation
profiles and dose response data. However, as with the PT assay,
those readouts, whether characterized as unusual or typical, are
opaque as to the origins of their features and as to why one
individual appears the same or different from another. For
example, a recent study has shown significant inter-individual
variability in the response to different anticoagulants when
assessed by a thrombogram methodology [14]. The modeling
based approach requires coagulation factor analyses of each
individual’s citrate plasma sample, but yields a representation of
an individual’s coagulation state that is easy to dissect, based on
dynamics reflecting proteins at their physiologic concentrations
and native conformations and well established mechanisms for
the anticoagulants. It is amenable to rapid screening of the
efficacy of available anticoagulants at a variety of concentrations
or possible combinations. Advances in measurement technology
to reduce the cost of coagulation factor composition analysis
should make this approach more feasible and enable pre and post
treatment assessments that should further individualize anticoag-
ulant therapy.
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Ethics
Population study 1 (dating to 2002) was approved by the
Institutional Review Board Committee on Human Research in the
Medical Sciences at the University of Vermont. All participants
gave informed written consent.
Population study 2 was approved by the Jagiellonian University
Ethical Committee. All participants gave informed written
consent.
Materials
Human fV, fVII, fVIIa, fIX, fX, antithrombin (AT) and
prothrombin were either obtained from Haematologic Technol-
ogies (Essex Junction, VT) or purified from fresh human plasma
using modifications of the methods of Bajaj et al. (fVII, fX, fIX
and prothombin) [36], Katzmann et al. (fV) [37] and Griffith et al.
(antithrombin) [38] or received as a gift (recombinant human
fVIIa) from Dr. Ula Hedner (Novo Nordisk, Denmark).
Recombinant fVIII, tissue factor pathway inhibitor (TFPI) and
recombinant tissue factor (Tf) (residues 1–263) were purchased
from American Diagnostica, Inc (Greenwich, CT) or received as
gifts: recombinant fVIII and recombinant Tf (residues 1–243)
from Drs. Shu Len Liu and Roger Lundblad (Hyland division,
Baxter Healthcare Corp, Duarte, CA) and recombinant full-
length TFPI from Dr. S. Hardy (Chiron Corp, Emeryville, CA).
1,2-Dioleolyl-sn-Glycero-3-Phospho-L-Serine (PS) and 1,2-Dio-
leoyl-sn-Glycero-3-Phosphocholine (PC) were purchased from
Avanti Polar Lipids, Inc (Alabaster, AL). Phospholipid vesicles
(PCPS) composed of 75% PC and 25% PS were prepared as
described [39]. Spectrozyme TH was purchased from American
Diagnostica, Inc (Greenwich, CT). The preparation of the Tf/
lipid reagent was performed as described [40]. Rivaroxaban
(XareltoH) was provided by Bayer HealthCare AG, Leverkusen,
Germany.
Populations
Study 1: Individuals have been described previously [15]: 9
male patients (68612 years) on stable warfarin anticoagulation
(0.16 to 10 years); and 5 apparently healthy male subjects (5167
years). Study 2: 47 patients (19 females, 28 males; age: 25-75 years)
on stable anticoagulation (mean time of 4 months) with warfarin
(2#INR#3). Indications for vitamin K antagonist administration
were atrial fibrillation (N=20), venous thromboembolism (N=20)
or aortic prosthetic valve implantation (N=7). The exclusion
criteria were recent (preceding 6 months) thromboembolic event,
acute infection, liver injury, renal insufficiency, autoimmune
disorders or known cancer. Three individuals had a thrombotic
event subsequent to the blood draw for compositional analysis.
Thirty-two apparently healthy individuals recruited from hospital
and university staff (Jagiellonian University Medical College,
Krakow, Poland) served as controls.
Blood Collection and Coagulation Protein Analyses
Fasting blood was drawn into 0.1 volume of 3.2% trisodium
citrate from an antecubital vein with minimal stasis. Citrated
blood samples were centrifuged within 15 minutes of collection
and stored in aliquots at –80 uC until further use. Factors II, V,
VII, VIII, IX, X were measured by one-stage clotting assays (Dade
Behring, Liederbach, Germany) using factor-deficient plasmas.
AT activity was measured using a Berichrom chromogenic assay
(Dade Behring). Free TFP) was determined using an ELISA
(Diagnostica Stago, Asnieres, France).
Computational Model
Computational simulations of Tf-initiated thrombin generation
profiles (cTGPs) were produced as described previously, with rate
constants reflecting measurements made at saturating phospho-
lipid for each phospholipid dependent process [16,41].
Incorporating pharmacologic agents
Anticoagulants were modeled by adding the appropriate sets of
equations (see Table 4) describing their activities to the existing
framework of differential equations. The rate constants employed
were as follows: UFH reaction with AT [26,29]; UFH-AT
reactions with fXa [24,42,43], fIXa [26], meizothrombin [44],
Tf-VIIa [27], fXa-fVa [43], and thrombin [44]; and Dansylargi-
nine-N-[3-ethyl-1,5-pentanediyl]amide (DAPA) reaction with
thrombin and meizothrombin [31]. Modeling of Fpx and
rivaroxaban interactions with their targets was conducted as
described previously [16].
Table 5. Anticoagulant efficacy and Tf concentration*.
Anticoagulant
TF Conc.
(pM)
Clot Time
(s)
Max Level
(nM)
Max Rate
(nM/s)
AUC
(nM*s)
Control 5 pM 173 436 3.4 93553
33% VKD{ 5 pM 371 97 0.7 25667
33% VKD{ 17.5 pM 177 151 1.6 25175
1.25 nM UFH 5 pM 322 161 0.7 53309
1.25 nM UFH 9 pM 176 205 1.3 48051
6 nM Riva 5 pM 358 323 1.8 94673
6 nM Riva 17.5 pM 174 484 4.3 93250
0.6 mM DAPA 5 pM 379 327 3.8 75670
0.6 mM DAPA 17.5 pM 176 450 8.3 79422
125 nM FPX 5 pM 360 334 1.9 91273
125 nM FPX 12.5 pM 171 477 4.2 89708
*Thrombin parameters were extracted from cTGPs at the indicated anticoagulant and Tf concentrations.
{VKD: Vitamin K dependent proteins for individual A are set to 33 percent of the person’s physiologic levels (other proteins remain at their individual specific levels).
doi:10.1371/journal.pone.0027852.t005
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A computationally derived thrombin generation profile (cTGP)
based on each warfarin-treated or control individual’s coagulation
factor composition was generated. Thrombin parameters (max
rate, max level, total thrombin (area under the curve, AUC) and
time to 10 nM total thrombin, the computational equivalent of clot
time in our empirical models) were extracted as described
previously [18] from each cTGP. Thrombin parameters from
each warfarin-treated individual (for example study 2: INR 2.0–
2.4: N=25) were then ratioed to the corresponding parameters
from every member of the relevant control group (study 2, N=32),
thus generating a characterization of each warfarin-treated
individual’s state of anticoagulation relative to the variation in
thrombin generation in a normal population. The means and
standard deviations for the four thrombin parameters, represent-
ing the entire ensemble of 800 values for each parameter were
then calculated.
With this approach, the time to 10 nM total thrombin
parameter allows a comparison of model predicted clot times
between each anticoagulated individual and all control individuals,
yielding a ratio value (the computational or cINR) analogous to
the ratio between a patient’s prothrombin time and that of a
standard plasma sample (INR).
Analyzing differences between the INR and cINR of
warfarin-treated individuals
The coagulation factor dependence of differences between
clinical INR and cINR values in each warfarin-treated individual
was investigated by establishing a metric defined as the (cINR-
INR)/INR, which quantified the relative disparity between model
and PT assay derived values. Each individual specific difference
was plotted against the corresponding level of a specific factor. A
series of plots testing all 8 factors was constructed and linear
regression analyses performed.
Hypothetical anticoagulation of 32 control individuals
Thrombin parameters were extracted as described previously
[18] from each cTGP representing a given individual from the
control population on a specific dose of an anticoagulant. In the
case of hypothetical warfarin anticoagulation, the concentrations
of the vitamin K dependent (VKD) proteins (fII, fVII/VIIa, fIX
and fX) were set to 25% or 33% their mean physiologic values
while the other factor levels remained at their individual specific
concentrations. Each thrombin parameter was then expressed
relative to the pretreatment value of that parameter for that
individual, yielding either a cINR or a percent change for other
parameters at a specific dose of anticoagulant. Group averages for
a given concentration of anticoagulant were then calculated for
each parameter using the ratio values.
Synthetic Coagulation Proteome
The procedure used has been described previously [6,16].
Relipidated Tf reagent at 5 pM final concentration was added to a
mixture of fII, fV, fVII, fVIIa, fVIII, fIX, fX, TFPI, and AT in
20 mM HEPES/150 mM NaCl with 2 mM CaCl2 containing
2 mM PCPS. Concentrations of factors and inhibitors were set to
those characterizing specific individuals. Pharmacologic agents
were incorporated into the reaction mixture prior to addition of
the Tf reagent.
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